---
title: Dr Robert Abraham Builds a Path into Regenerative Medicine
description: Cross Biologics founder Dr Robert Abraham partners with RRG to offer independent providers a single membership covering biologics, training and compliance.
author: Darie Nani (Editor-in-Chief)
date: 2026-02-20T13:18:45.000Z
updated: 2026-03-20T20:08:30.050Z
canonical: https://www.sovereignmagazine.com/article/dr-robert-abraham-builds-a-path-into-regenerative-medicine
image: https://cdn.nanimediahouse.com/abraham-headshot.webp
categories: Science & Tech
content_type: Profile
region: United States
publication: Sovereign Magazine
about:
  - type: Person
    name: Dr Robert Abraham
    description: Founder of Cross Biologics, based in Orlando, Florida. Leads the company’s sales coaching programme and works directly with member clinics during the 12-week Regen Revenue Accelerator.
    jobTitle: Founder
    worksFor: Cross Biologics
---

Cross Biologics, founded by Dr Robert Abraham in Orlando, Florida, has partnered with Regenerative Research Group (RRG) to give independent healthcare providers a single membership covering everything they need to launch a regenerative medicine practice: premium biologic products sourced and tested by RRG, clinical training, compliance documentation and sales coaching. Member clinics receive up to 15 per cent savings on wholesale pricing.

Regenerative treatments (exosome therapies, extracellular matrix procedures, secretome infusions) are among the fastest-growing service lines in outpatient medicine, but most independent providers (chiropractors, pain clinics, medical spas, nurse practitioners) cannot enter the market without significant upfront investment in products, training and regulatory compliance. The Cross Biologics–RRG partnership eliminates that upfront cost by packaging everything into a membership.

## The Gap Abraham Identified

The regenerative biologics market has a structural problem. Product manufacturers sell to distributors, who sell to clinics, but nobody in that chain teaches clinics how to build a profitable regenerative practice. Providers buy product and then face three immediate challenges: developing clinical protocols, navigating FDA compliance and converting patients who are unfamiliar with treatments priced between $3,000 and $10,000 per session.

Abraham could build the coaching and compliance training, but he needed a supply partner with ethically sourced products, rigorous testing standards and FDA-registered processing. RRG provided that. The partnership pairs Abraham’s implementation expertise with RRG’s product infrastructure: OBGYN-sourced biologics, CLIA-certified labs, third-party viability testing and documented chain-of-custody from tissue collection through to delivery.

The result is a company that sits across all three challenges simultaneously. Cross Biologics is a distributor (through RRG), a training provider, a compliance consultant and a sales coach. That combination is unusual in the biologics supply chain.

## RRG’s Three Biologic Platforms

RRG supplies three product categories, all sourced through partnerships with board-certified OBGYNs and processed in FDA-registered, CLIA-certified laboratories.

**EXM (Extracellular Matrix)** products are derived from perinatal tissues including placenta and umbilical cord. These scaffold-like materials support tissue regeneration by providing structural proteins and growth factors at the treatment site.

**EXO (Exosomes)** is a line of five targeted formulations (EXO-Elite, EXO-Hair, EXO-Skin, EXO-PV-MAX and EXO-MOVE) covering hair restoration, skin rejuvenation and musculoskeletal recovery. Exosomes are nanoscale vesicles that carry signalling molecules between cells, and the specialised formulations allow clinics to market distinct treatment lines.

**EXS (Acellular Secretome)** offers growth factors and extracellular vesicles at a lower price point than EXM or EXO, designed as an entry-level product for clinics testing the regenerative market.

Each batch undergoes third-party viability testing, and RRG maintains documented chain-of-custody protocols from tissue collection through to delivery. These sourcing and testing standards are central to the partnership’s value: they give Cross Biologics members supplier-side compliance documentation that would be expensive and time-consuming to verify independently.

## From Signup to Revenue in 12 Weeks

While RRG handles product supply and sourcing compliance, Abraham’s contribution is the implementation side. The Regen Revenue Accelerator (RRA) is a 12-week coaching programme that takes providers from initial onboarding to active regenerative practice, covering staff training, consultation workflow design, compliance guidance and weekly one-on-one sales coaching with Abraham himself.

The sales coaching addresses what Abraham sees as the biggest barrier for most clinics: patient conversion, not clinical knowledge. Regenerative treatments are premium-priced and unfamiliar to most patients, which requires a consultation approach that most primary care or chiropractic practices have not needed before. The RRA trains providers to explain the clinical rationale, set expectations and handle pricing conversations.

Support continues beyond the initial 12 weeks with ongoing growth strategy and compliance updates as the [regulatory landscape](https://www.sovereignmagazine.com/article/2024-a-year-of-positive-change-ethical-considerations-in-wellbeing-healthcare) for regenerative products evolves.

## Why Compliance Is Central to the Partnership

The regulatory environment for regenerative biologics in the United States is actively enforced. The FDA classifies exosome products used to treat diseases as drugs and biological products under the Public Health Service Act, subject to premarket review requirements. The agency has issued warning letters to companies marketing unapproved exosome products and has stated that no exosome products are currently FDA-approved for clinical use.

For Abraham, this regulatory pressure makes the RRG partnership more valuable, not less. RRG’s FDA registration, CLIA certification, OBGYN sourcing partnerships and documented testing protocols provide a compliance layer that independent clinics would struggle to build on their own. Abraham pairs that with practice-level compliance training through the RRA, covering documentation, patient consent workflows and regulatory updates.

His argument is that independent providers need a single partner who can handle product supply, regulatory documentation, clinical training and business development together, and that the tighter FDA enforcement becomes, the more valuable that bundled approach will be.

## In case you were wondering…

**Q: Is exosome therapy considered regenerative medicine?**
Exosome therapy falls within the broader category of regenerative medicine. Exosomes are extracellular vesicles (nanoscale particles released by cells) that carry proteins, lipids and genetic material capable of influencing recipient cell behaviour. Research published in journals including Stem Cell Research and Therapy has demonstrated their potential in tissue repair, anti-inflammatory response and wound healing. Unlike stem cell therapies that introduce living cells, exosome-based treatments use cell-derived signalling molecules, which reduces rejection risk and simplifies storage and transport logistics.

**Q: How much does exosome therapy typically cost?**
Individual exosome treatments range from $3,000 to $10,000 per session depending on the clinic, treatment area and number of sessions required. Pricing varies significantly because there is no standardised national pricing framework for regenerative biologics in the United States. Bulk purchasing programmes (like the one offered through Cross Biologics’ RRG partnership) aim to reduce per-unit cost for providers, which can translate to lower patient pricing or improved margins for the practice.

**Q: Are exosomes subject to FDA regulation in the United States?**
The FDA classifies exosomes used to treat diseases and conditions as drugs and biological products under the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. They are subject to premarket review and approval requirements. The agency has issued warning letters to companies marketing unapproved exosome products and has stated that no exosome products are currently FDA-approved for any clinical use. Providers should verify that their suppliers maintain proper registration, testing documentation and chain-of-custody records.

**About Dr Robert Abraham**
Founder, Cross Biologics

Founder of Cross Biologics, based in Orlando, Florida. Leads the company’s sales coaching programme and works directly with member clinics during the 12-week Regen Revenue Accelerator.